LegalAug 5, 2026, 04:30 PM
XTL Biopharmaceuticals Faces Shareholder Derivative Claim Motion
AI Summary
XTL Biopharmaceuticals Ltd. announced it was served with a shareholder motion seeking court authorization to file a derivative claim. The claim targets the company's controlling shareholder and certain current and former directors and officers, alleging breaches of duties related to the 2024 acquisition of The Social Proxy Ltd., which is now in liquidation. The petitioner seeks approximately NIS 100 million in monetary compensation, among other relief. XTL Biopharmaceuticals stated it believes the motion is meritless and plans to respond accordingly.
Key Highlights
- XTL Biopharmaceuticals was served with a motion on August 3, 2026, for a derivative claim.
- The motion seeks court authorization to file a derivative claim against the controlling shareholder and certain directors/officers.
- Allegations include breach of duties related to the 2024 acquisition of The Social Proxy Ltd.
- The Social Proxy Ltd. is currently in liquidation since February 22, 2026.
- The petitioner seeks monetary compensation estimated at NIS 100 million for the alleged destruction of the subsidiary's value.
- The company believes the motion is meritless and intends to respond fully.
Price Impact
More from XTLB